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Impacts 
• Antimicrobials are widely used in food-producing animals, posing a potential risk of spread 
of antimicrobial resistant bacteria from animals to humans. Frequent use of certain 
antimicrobials in food animals may reduce their effectiveness as treatments for both animals 
and humans. 
• Intensive collaboration and dialogue between dairy producers, veterinarians, industry 
partners and researchers led to the development of an antimicrobial stewardship policy 
including practical measures designed to deliver real, on-farm changes in antimicrobial use, 
while maintaining or improving dairy herd health and welfare. 
• Although many producers were already stringent in their antimicrobial use (many were 
organic dairy farmers), almost 60% envisaged making changes to their use of antimicrobial 
medicines on farm as a result of their participation in the policy development process. 
 
Summary 
Pressures for more responsible use of antimicrobial (AM) medicines in food animals are likely to 
increase from policy makers and the food industry, including retailers. To address this challenge, 
participatory approaches to welfare interventions and disease prevention may also be necessary 
alongside more conventional regulatory measures. 
This paper describes the process of enabling groups of dairy producers to use a participatory policy-
making (PPM) approach to develop an AM stewardship policy. The policy includes measures agreed to 
by all producers for more responsible use of AMs, while maintaining or improving dairy herd health 
and welfare. 
This process provided a unique opportunity for collaboration and dialogue between producers, 
veterinarians, industry and researchers. Its participatory nature encouraged comprehensive learning for 
all involved. This integration of science with producers’ knowledge and experience led to credible and 
practical recommendations designed to deliver real and lasting change in AM use. 
The multidisciplinary nature of this research marks a significant contribution to embedding social 
science skills and approaches into the veterinary sphere. As an initial step in creating better 
understanding of how participatory approaches with farmers can be applied in a UK context and more 
widely, this work serves as a pilot for promoting more responsible use of veterinary medicines in other 
livestock species.   
Key words  
Antimicrobial resistance; public health; participation; antimicrobial stewardship policy; dairy 
production; veterinary medicine use. 
 
Introduction  
The increase of antimicrobial resistance (AMR) is a growing problem for human health and an 
increasing economic burden for society (Laxminarayan et al., 2013). Antimicrobials (AMs) are widely 
used in food-producing animals (O'Neill, 2015) and this has led to growing concern. There is a risk of 
spread of AMR bacteria from animals to humans, and the frequent use of certain AMs in food animals 
may reduce their effectiveness for treatment in humans (EFSA, 2015). Increasing resistance also has an 
adverse effect on the livestock sector, leading to more recalcitrant bacterial infections in food-producing 
animals, increased costs of treatment, productivity losses and animal welfare concerns (McEwen & 
Fedorka-Cray, 2002). 
 
High use of AMs in food-producing animals is often associated with intensive pig and poultry 
production, and use of AMs in dairy cattle may not be seen as an immediate concern (Raymond et al., 
2006; Brunton et al., 2012). However, the use of AMs, including those of major importance to treat 
serious infections in humans (fluoroquinolones, 3rd and 4th generation cephalosporins and long-acting 
macrolides; WHO, 2012), are commonplace in dairy systems (Raymond et al., 2006; Brunton et al., 
2012). The majority of AMs in dairy cattle are administered for the treatment of mastitis during lactation 
and at cessation of lactation, dry cow therapy (Swinkels et al., 2015). A survey of AM usage on dairy 
farms in the United Kingdom (UK) revealed that antibiotic tubes used for treating mastitis frequently 
contain 4th generation cephalosporins, and that a large number of dairy producers fed their calves waste 
milk from cows with mastitis that were potentially undergoing treatment with these AM families 
(Brunton et al., 2012).  
 
The UK currently has no governmental regulations to reduce veterinary AM use similar to those 
introduced in Netherlands in 2010, which required farms to reduce veterinary antibiotic use by 50% by 
2013 and 70% by 2015 (as compared with the amounts that had been used in 2009; Speksnijder et al., 
2015b). The only UK regulatory measures are voluntary measures to ensure best practice and 
responsible use through farm assurance schemes and compliance to retailer standards for meat and 
animal products, as described in the UK Five Year AM Strategy 2013 to 2018 (Davies & Gibbens, 
2013). Several major retailers and milk buyers in the UK have or are in the process of setting their own 
guidelines regarding the use of AMs. For example, one milk buyer recently introduced a requirement 
for their suppliers to use selective rather than universal dry cow therapy, and some retailers are already 
monitoring the use of 3rd and 4th generation cephalosporins and fluoroquinolones (Alderton, 2015). 
Recently, the Responsible Use of Medicines in Agriculture (RUMA) Alliance - consisting of 24 
organizations along the value chain, including farmer representative organizations, retailers, veterinary 
practices, farm assurance organizations and animal welfare organizations - published guidelines for 
more responsible use of AMs by cattle farmers (RUMA, 2015).  
 
Pressures to reduce AM use and to use AM medicines more responsibly in food-producing animals are 
likely to increase from policy makers and the food industry, including retailers. To address this 
challenge, participatory approaches to welfare interventions and disease prevention may also be 
necessary to achieve sustainable farm practice change in addition to more conventional regulatory 
methods (Buller et al., 2015). Participatory approaches - in particular participatory policy-making 
(PPM) - offers innovative solutions to the AMR challenge and fills the void in public policy making 
regarding this challenge. These approaches shift the view of farmers as merely policy implementers to 
viewing farmers as active partners in collaborative decision making and joint learning processes with 
other stakeholders to identify and develop solutions together (Schut et al., 2014; Sutton, 1999). Karl 
(2002) states “PPM implies empowerment of stakeholders to take part in the whole cycle of the policy 
process: formulation, implementation, monitoring and evaluation of policy”. Solutions developed by 
farmers through these approaches often lead to on-farm practice change as they are more practical and 
implementable than solutions developed by outsiders (Pretty, 1995; Chambers et al., 1989). Moreover, 
they allow farmers to maintain control and a sense of ownership over the solutions (Escobar & Buller, 
2014). Evidence of successful PPM can be found in a number of areas, from citizen participation in local 
governance to environment management (Van den Hove, 2000).   
 
This paper describes a policy development process in which two groups of dairy producers and their 
veterinarians were actively encouraged and enabled to work together to develop their own AM 
stewardship policy leading to changes in farming practice and reduced AM use. 
 
Materials and methods 
The policy development process was initiated by two dairy producer groups, a group of 25 organic 
producers and a group of 48 conventional producers. These two groups exclusively supply one major 
retailer in the UK. From the outset, the process was a focused initiative driven by producers as a 
collective, and all producers in the two groups participated in the policy development process to ensure 
ownership of the policy. The producer groups aimed to develop an enactable on-farm AM stewardship 
policy that showed their commitment and responsibility to the milk buyer and retailer to reduce and 
rationalise AM use without compromising animal health and welfare. 
 
The leaders of the producer groups and their lead veterinary advisor initiated the formation of a project 
team which also included a representative from the retailer and milk buyer and researchers. A facilitator 
was contracted to guide the policy development process (Figure 1). A series of meetings and workshops 
were held over the period May to August, 2015 to conceive and develop the policy. The first team 
meeting was held in May, 2015 to identify policy objectives and policy areas, to clarify specific terms 
(e.g. What do we mean by responsible use?) and to reach agreement on how to engage all producers in 
the policy making process (Figure 1, Step 3). Taking workshop costs, group size as well as travel time 
for producers to the workshop into consideration, it was agreed to organize four regional workshop, with 
each workshop comprising 20 to 25 producers and their veterinarians. The project team developed an 
outline for the regional workshops and structured the main discussions around on-farm measures for 
more responsible use of AMs within four categories (policy principles), based on a conceptual model 
derived from Speksnijder and colleagues (2015a): 1. disease management strategies, 2. ensuring correct 
use of medicines, 3. avoiding prophylactic use and 4. ensuring quality data recording and use. These 
categories provided an initial framework for policy development.  
 
The regional workshops (Figure 1, Step 4) were key in the development of the policy, and were held in 
June, 2015. Each regional workshop began with a presentation by the lead veterinary advisors to provide 
insights into AMR and why it mattered to farmers, the dairy industry and the world. As part of this 
presentation, a survey was conducted amongst producers and veterinarians using an interactive audience 
response system (Turning Point 5, Turning Technologies, Belfast, UK) to pose multiple-choice 
questions to which the attendees could respond. The answers to these questions were amalgamated in 
order to better understand the perception of producers and their veterinarians on the use of AMs and 
AMR as well as to raise their awareness on the issue and compare and contrast the different levels of 
awareness represented. These question sessions were followed by short focus group discussions to create 
a better understanding of the benefits and challenges of current AM use on farms.  
The main part of the workshop consisted of group discussions to identify practical measures that could 
ensure responsible (and often reduced) use of AMs on farm in each category. Workshop participants 
were divided into smaller groups, with producers and veterinarians kept in separate groups to ensure 
producers felt comfortable to actively participate in the discussion (Morgan, 1996) as well as to manage 
veterinary-client communication dynamics (Shaw, 2004) and thus reduce bias in responses. Participants 
were requested to discuss and write down practical measures on sticky note paper (one strategy per 
sticky note). After exhaustion of new ideas, each group was asked to rank the measures they had 
identified according to ease of implementation on farms. Each group presented their measures in the 
four categories, and all sticky notes (per category) were then combined. General plenary discussion 
followed with both producers and veterinarians in order to further develop and agree on the measures 
presented. The facilitator consolidated the outcomes of the four workshops, and the project team met in 
July, 2015 to draft an initial policy document. Further feedback on this initial document was achieved 
through a follow-up meeting at the beginning of August, 2015 with a representation of producers from 
each region to refine the policy (Figure 1, Steps 5 and 6).  
 
Figure 1. Outline of the process followed to develop an antimicrobial stewardship policy with dairy 
farmers in the UK 
 
After final review by the lead veterinarian and producer group leaders at the end of August, 2015 (Figure 
1, Step 7), the policy was communicated by email to all producers in the two producer groups (Figure 
1, Step 8), and policy implementation tools were developed (Figure 1, Step 9). The two groups then 
began the policy implementation (Figure 1, Step 10).  
 
Results  
The turnout at all regional workshops was high: 97 participants (70 producers out of a total of 73 in the 
two producers groups) and 27 veterinarians, from all practices servicing the farms participated.   
 
Perception of producers and their veterinarians on the use of AMs and AMR 
Producers and their veterinarian were responsive and aware of the problem of AMR. When asked 
whether they agreed or disagreed with the statement that “AMR is just a fashionable topic and a passing 
fad”, 80% (76/95) disagreed with this statement.  
 
In terms of antibiotic use, 79% (75/95) agreed with the statement that antibiotic use in the UK livestock 
sector is too high. Asking specifically about whether they perceived that there were AMR bacteria on 
dairy farms, 46% (44/97) of the respondents estimated the percentage of UK dairy farms with AMR 
bacteria as 25 % or less (Figure 2), whilst 23% (22/97) of the respondents estimated the percentage of 
UK farms with AMR bacteria as 100%. Narrowing down whether producers thought there was AMR 
on their own farm, 41% (36/87) of the producers and their veterinarians thought there was mild AMR 
on their farms, and 36% (31/87) thought there was moderate AMR on their farms (none 1%, very limited 
18%, and severe 3%). 
 
Figure 2. Participants’ response to the question to estimate the presence of AMR bacteria on UK dairy 
farms 
 
In the fight against AMR, producers and veterinarians indicated that they see the role of veterinarians 
as being somewhat more important than the role of producers (Figure 3). In response to a question about 
the importance of the role of the producer in the fight against AMR, 70% (68/97) of respondents 
indicated that the role of farmer was very important. This is compared with the response to a similar 
question about the importance of the role of the veterinarian in the fight against AMR, where 87% 
(84/97) of the respondents indicated the role of the veterinarian was very important 
 
Figure 3. Participants’ response to the question about the importance of the role of the producer and 
the veterinarian in the fight against antimicrobial resistance  
An important question for the future success of the policy development process was whether the 
producers felt able to reduce the amount of AMs they used on their farm whilst also maintaining the 
same production levels and health of their herds. 73% (71/97) of respondents indicated they felt they 
were able to reduce the amount of AMs on their farms.  
 
In the third and fourth regional workshops, a specific question was added. Producers and the 
veterinarians were asked whether or not they felt they could specifically reduce the use of AMs of major 
importance to treat serious infections in humans; 53% (27/51) indicated they could.  
 
Antimicrobial Stewardship Policy  
A conceptual model originally developed by Speksnijder and colleagues (2015a) was adapted by the 
project team to provide a structure (core principles) around which the final stewardship policy was 
developed:  
Principle 1: Disease reduction strategies 
Principle 2: Ensuring correct use of medicines  
Principle 3: Avoiding prophylactic use 
Principle 4: Encouraging quality data recording and use 
Based on the strategies discussed during the workshops, policy-specific and practical measures were 
developed (Table 1). Practical measures were organised under the following policy statements, which 
were developed during subsequent meetings with the producer representatives after the regional 
workshops. These policy measures adhered to the above-mentioned principles, and were stated in active 
forms.  
• All producers use animal production practices that reduce, and, where possible, eliminate the 
need for AM therapies. 
• All producers work with their veterinarians to assess and address disease risk regularly. 
• On all farms, all staff engaged in using antibiotics use them responsibly or are adequately 
supervised by staff who are able to do so.  
• On all farms, the use of antibiotics to prevent disease is minimalised.  
• On all farms, unified data is collected and used to benchmark and compare medicine use within 
and between farms in order to work towards further reductions in AM use. 
The term ‘responsible use’ was clarified to reflect an individual as being able to identify the correct 
animal to treat (only treating infections), as well as identifying the correct product to use at the correct 
dose (amount) and correct duration (including initiating treatment at the right time).  
 
Table 1. Policy measures - Antimicrobial Stewardship Policy, Year 1 
 
Whilst developing the policy, it became clear that, within the producer groups there was only limited 
information available as to the levels of AM use on farms. Hence, some of the policy measures could 
only be defined if more detailed information on current use was available. Thus it was decided that the 
measures agreed on would initially only apply to the first year of implementation, and that  the policy 
would be updated and reviewed on a yearly basis as the understanding of use on farms develops and 
scientific evidence on the subject grows.  
 
Participation in the policy development process  
Evaluations at the end of the workshops indicated a consistently positive response from participants 
(Figure 4). Comments provided on the benefits of participating in the workshop included:  
 “made me think about antibiotic use more”  
“knowing the opinions of my fellow producers” 
 “ideas for moving our practice forward, using drug usage as part of the Herd Health Plan”   
“helped develop policies to advantage all parties” 
“helped make policy that works for the farmer”   
 
Figure 4. Participant’s response to regional workshop evaluation questions 
(note: Question 4 was left blank by some respondents as this question was not relevant for 
veterinarians.) 
 
Although generally very positive about the workshops, participants also felt that the development of 
such a policy was difficult and mentally taxing. Scoring their experience from 1 (not at all challenging) 
to 10 (very challenging), over 42% (33/78) of participants gave a score of 8 and higher as to whether 
they felt participation in this process was challenging. More than half of producers (58%; 45/78) gave a 
score of 8 or more as to whether they envisaged making any changes to their use of AM medicines on 
farm as a result of their participation in the workshops. Changes mentioned by producers and 
veterinarians included:  
 “more targeted approaches” 
 “further reduction in use of cephalosporin, more selective dry cow therapy” 
 “selective dry cow therapy, bacteria testing on farm” 
 “better storage and disposal of partly used AMs” 
“reduce use of Naxcel (ceftiofur, a 3rd generation cephalosporin) 
 “more prevention” 
“stop using Marbocyl (marbofloxacin, a fluoroquinolone) and Cobactan (cefquinome, a 4th 
generation cephalosporin) injectables” 
“changing dry cow therapy, reducing 3rd and 4th generation AMs ” 
 
Discussion 
This is the first known application of PPM to livestock health policy. The policy development process 
provided a unique opportunity for intensive collaboration and dialogue between producers, 
veterinarians, industry partners and researchers. The participatory process provided comprehensive 
learning for all involved, and allowed for the integration of science and the producers’ own knowledge 
and experience. The process led to the development of credible and practical recommendations designed 
to deliver real on-farm changes in antibiotic use. Achieving genuine and effective change in AM use 
depends upon the collaborative engagement of farmers, veterinarians, and other actors along the value 
chain, including milk buyers and retailers (Buller et al., 2015).  
 
Although evidence of substantive increases in AMR bacteria in the dairy sector is currently limited 
(EFSA, 2015; Landers et al., 2012), three quarters of producers (and their veterinarians) in this survey 
thought that they had mild to moderate levels of AMR on their farm. This result brings up a number of 
other questions: On what evidence is this claim being made? Are farmers and veterinarians experiencing 
reduced effectiveness of AMs on their farms, or is their perception of this issue driven by media or by 
the concern of the retailer they supply? 
 
In developing the practical policy, there was a tension between the producers’ commitment to set 
common and consistent measures as a group and their individual desire to retain personal autonomy of 
action. Producers were willing to commit to the policy measures; however, how each measure was to 
be implemented and achieved on farm needed to be farm-specific and in the hands of the individual 
producer. As a result of this tension, the measures adopted were less prescriptive in nature than, for 
example, the RUMA guidelines. Being less prescriptive should not necessarily mean less effective, 
however, as Biggs and colleagues (2016) have shown less prescriptive and more bespoke criteria to 
select cows for dry cow therapy on dairy farms can lead to better results in terms of reduced AM use. 
Comparing the adopted policy measures in the current study with the RUMA guidelines revealed that 
most aspects indicated in the guidelines had been included. Those specific issues which were not 
included were nevertheless discussed within the workshops. For example, keeping closed herds (where 
no introductions of new animals are made in order to ensure biosecurity) was tabled, but was not 
considered possible for all producers, particularly those with organic herds.  
 
Discussions over what measures to include and how best to achieve these measures was challenging at 
times. One particular area of difficulty for farmers was maintaining a coherent and correct policy of 
medicine use when staffing was often inconsistent and changing (particularly with the use of relief 
milkers or casual workers). Contrary to human health where those who administer medicines need to 
have a licence or specific training, in the farming sectors of the UK, AMs prescribed by the veterinarian 
are largely administered by producers and farm staff. Producers indicated they were able to ensure their 
permanent staff had the appropriate qualification and training relevant to administering AMs, however 
this was seen as much more of a challenge when using temporary relief workers. Thus, making certain 
that the correct animal is treated, with the right dose, at the right time and right duration becomes more 
difficult. The producers agreed to overcome this by defining clear responsibilities regarding AM use 
and having clear AM decision trees with protocols for applicable diseases in the relevant languages for 
the nationalities of the relief workers.  
 
Although recording AM use on farms is required by law (DEFRA, 2012), producers in the UK have few 
methods to aggregate these records, therefore little comprehensive data is available which relates to AM 
use on individual or group levels. For this reason, there is at present no clear understanding of AM use 
per individual animal on UK farms. Medicine data recording is a mandatory requirement in the Royal 
Society for the Prevention of Cruelty to Animals and Soil Association standards as part of farm 
assurance in the Herd Health Plan (Hemsworth et al., 2009). However, differences in recording practice, 
little agreement on choosing specific numerators or denominators, and the absence of a single universal 
recording system used by all group members was a limitation. During the policy development process, 
producers realised that to be able to set realistic reduction targets (Key Performance Indicators) and to 
benchmark AM use well, they would have to gain a better understanding of how medicines were being 
used on both individual and group levels. Also, currently in the UK, there are few methods of 
systematically integrating farm management and veterinary data. The producer groups therefore agreed 
that in the first year of policy implementation, the focus would first be to collate and use all on-farm 
data for analysis.  
 
Through the four regional workshops, all producers in the two groups participated in the process. It is 
anticipated, however, that engaging all producers of a particular group in the PPM process might not 
always be practical. Initial discussions have now been held with sheep and beef producer groups 
supplying the same retailer to implement a similar policy development process. Working with these 
groups will bring a new set of challenges, as the number of producers are much larger and more 
geographically diverse. Other challenges in terms of transferability of the PPM approach relate to the 
efficacy of producers. The belief of producers in their own ability to make a change is essential for the 
success of this process. The participating dairy producers felt they had the power and autonomy to make 
changes on their farms; this, however, might not be the case in all livestock sectors nor in all countries. 
Particularly in the poultry and pig sectors, producers are less autonomous and might not feel empowered 
enough to make this process a success. Further work using the PPM approach in different contexts and 
settings is necessary to explore transferability of the approach.  
 
Concluding Remarks  
This research provides insight on how to enable groups of dairy producers to conceive, design and 
implement AM stewardship policies to address the challenge of more responsible use of medicines on 
farms, while maintaining or improving dairy herd health and welfare. As an initial step in creating better 
understanding of how participatory approaches with producers can be applied in a UK context and more 
widely, this work serves as a pilot for promoting more responsible use of AMs in other livestock species.  
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